Get the Stockscreener App
3.14
2.79%
-0.09
After Hours:
3.21
0.07
+2.23%
Nanobiotix Adr stock is traded at $3.14, with a volume of 16,731.
It is down -2.79% in the last 24 hours and down -28.64% over the past month.
Nanobiotix SA is a clinical-stage biotechnology company that has one operating segment, which focuses on developing product candidates that use its proprietary nanotechnology to transform cancer treatment by increasing the efficacy of radiotherapy. The company develops NanoXray products to help patients receiving radiotherapy by magnifying the effect of radiotherapy within tumor cells without increasing the dose to surrounding healthy tissues. Its product candidate is NBTXR3, a preclinical research program for cancer immunotherapies.
See More
Previous Close:
$3.23
Open:
$3.11
24h Volume:
16,731
Relative Volume:
1.87
Market Cap:
$149.32M
Revenue:
$27,600
Net Income/Loss:
$-36.04M
P/E Ratio:
-1.7718
EPS:
-1.7722
Net Cash Flow:
$-1.66M
1W Performance:
-10.29%
1M Performance:
-28.64%
6M Performance:
-55.40%
1Y Performance:
-45.96%
1-Day Range:
$3.0272
$3.2117
1-Week Range:
$3.0272
$3.47
52-Week Range:
$3.0272
$8.962
Nanobiotix Adr Stock (NBTX) Company Profile
Compare NBTX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NBTX
Nanobiotix Adr
|
3.14 | 149.32M | 27,600 | -36.04M | -1.66M | -0.7968 |
|
VRTX
Vertex Pharmaceuticals Inc
|
465.73 | 119.71B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
762.34 | 82.77B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
617.49 | 36.87B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
253.01 | 32.63B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
117.20 | 28.10B | 3.30B | -501.07M | 1.03B | -2.1146 |
Nanobiotix Adr Stock (NBTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-28-24 | Initiated | Guggenheim | Buy |
| Dec-08-23 | Initiated | Leerink Partners | Outperform |
| Jan-06-21 | Initiated | Evercore ISI | Outperform |
Nanobiotix Adr Stock (NBTX) Latest News
NANOBIOTIX Provides Third Quarter 2024 Update and Progress on Nanotherapeutics Platforms - GlobeNewswire Inc.
Nanobiotix (NASDAQ:NBTX) Trading Down 14% - Defense World
Nanobiotix (NASDAQ:NBTX) Stock Price Down 14% - MarketBeat
Nanobiotix S.A. (NASDAQ:NBTX) Forecasted to Earn FY2025 Earnings of $0.88 Per Share - MarketBeat
Earnings call: Nanobiotix reports Q1 2024 results, advances with NBTXR3 By Investing.com - Investing.com
Nanobiotix Announces Latest Share and Voting Rights UpdateTipRanks.com - TipRanks
Nanobiotix Prepares to Unveil Q1 2024 ResultsTipRanks.com - TipRanks
Nanobiotix's Revenue at Risk: The High Stakes of Sole Dependence on Janssen PartnershipTipRanks.com - TipRanks
Nanobiotix Advances NBTXR3 for Lung Cancer TreatmentTipRanks.com - TipRanks
NANOBIOTIX Reports New Data for Potential First-in-Class Radioenhancer NBTXR3 in Combination With Anti-PD-1 Showing Local or Distant Tumor Regression in 76.9% of Evaluable Patients Regardless of Prior Anti-PD-1 Exposure - Business Wire
NANOBIOTIX Partners With LianBio to Develop and Commercialize Potential First-in-Class Radioenhancer NBTXR3 Across Tumor Types and Therapeutic Combinations in China and Other Asian Markets - Business Wire
IPO Launch: Nanobiotix S.A. Pursues $96 Million IPOIPOs On TheStreetU.S. IPO Research & Opinion - TheStreet
NBTX News Today | Why did Nanobiotix stock go down today? - MarketBeat
Nanobiotix (NBTX) Stock Price, News & Analysis - MarketBeat
Nanobiotix - Massachusetts Biotechnology Council
Nanobiotix Adr Stock (NBTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.58%
1.81%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):